© The Canadian Journal of Urology™; 21(Supplement 2); June 2014
63. Neischlag E, Behre HM, Bourchard P et al. Testosterone
replacement therapy: current trends and future directions.
Hum Reprod Update
2004;10(5):409-419.
64. Srinivas-Shankar U, Roberts SA, Connolly MJ et al. Effects
of testosterone on muscle strength, physical function, body
composition, and quality of life in intermediate-frail and frail
elderly men: a randomized, double-blind, placebo-controlled
study.
J Clin Endocrinol Metab
2010;95(2):639-650.
65. Isidori AM, Giannetta E, Greco EA et al. Effects of testosterone
on body composition, bone metabolism and serum lipid profile
inmiddle-agedmen: ameta-analysis.
Clin Endocrinol (Oxf)
2005;
63(3):280-293.
66. Travison TG, Basaria S, Storer TWet al. Clinical meaningfulness
of the changes in muscle performance and physical function
associated with testosterone administration in older men
withmobility limitation.
J Gerontol ABiol Sci Med Sci.
2011;66(10):
1090-1099.
67. Fernández-Balsells MM, Murad MH, Barwise A et al. Adverse
effects of testosterone therapy in adult men: a systematic review
and meta-analysis.
J Clin Endocrinol Metab
2011;96:905-912.
68. Rhoden EL, Morgentaler A. Risks of testosterone-replacement
therapy and recommendations formonitoring.
NEngl JMed
2004;
350(5):482-492.
69. Roddam AW, Allen NE, Appleby P, Key TJ. Endogenous
HormonesandProstateCancerCollaborativeGroup.Endogenous
sex hormones and prostate cancer: a collaborative analysis of
18 prospective studies.
J Natl Cancer Inst
2008;100(3):170-183.
70. Shabsigh R, Crawford ED, Nehra A, Slawin KM. Testosterone
therapy in hypogonadal men and potential prostate cancer risk:
a systematic review.
Int J Impot Res
2009;21(1):9-23.
71. MorgentalerA, TraishAM. Shifting the paradigmof testosterone
and prostate cancer: the Saturation Model and the limits of
androgen-dependent growth.
Eur Urol
2009;55(2):310-320.
72. Morgentaler A, Lipshultz LI, Bennett R, Sweeney M, Avila D Jr,
Khera M. Testosterone therapy in men with untreated prostate
cancer.
J Urol
2011;185(4):1256-1260.
73. Vigen R, O’Donnell CI, Baron AE et al. Association of
testosterone therapy with mortality, myocardial infarction, and
stroke in men with low testosterone levels.
JAMA
2013;310(17):
1829-1836.
74. Finkle WD, Greenland S, Ridgeway GK et al. Increased risk of
non-fatal myocardial infarction following testosterone therapy
prescription in men.
PLoS One
2014;9(1):e85805.
75. Ioannidis JP. Contradicted and initially stronger effects in
highly cited clinical research
. JAMA
2005;294(2):218-228.
76. Morgentaler A, Kacker R. Testosterone and cardiovascular
risk—deciphering the statistics.
Nat Rev Urol
2014;11(3):131-132.
77. Basaria S, Coviello AD, Travison TD et al. Adverse events
associated with testosterone administration.
N Engl J Med
2010;
363(2):109-122.
78. Traish AM, Guay AT, Morgentaler A. Death by testosterone?
We think not!
J Sex Med
2014;11(3):624-629.
79. Oskui PM, French WJ, Herring MJ, Mayeda GS, Burstein S,
Kloner RA. Testosterone and the cardiovascular system:
a comprehensive reviewof the clinical literature.
J AmHeart Assoc
2013;2(6):e000272.
80. English KM, Steeds RP, Jones TH, Diver MJ, Channer KS.
Low-dose transdermal testosterone therapy improves angina
threshold in men with chronic stable angina: A randomized,
double blind, placebo-controlled study.
Circulation
2000;102(16):
1906-1911.
81. Stout M,Tew GA, Doll H et al. Testosterone therapy during
exercise rehabilitation inmale patients with chronic heart failure
who have low testosterone status: a double-blind randomized
controlled feasibility study.
Am Heart J
2012;164(6):893-901.
82. Shores MM, Smith NL, Forsberg CW, Anawalt BD, Matsumoto
AM. Testosterone treatment and mortality in men with low
testosterone levels.
J Clin Endocrinol Metab
2012;97(6):2050-2058.
83. Muraleedharan V, Marsh H, Kapoor D, Channers KS, Jones TH.
Testosterone deficiency is associated with increased risk of
mortality and testosterone replacement improves survival in
men with type 2 diabetes.
Eur J Endocrinol
2013;169(6):725-733.
84. Edelstein D, Basaria S. Testosterone undecanoate in the
treatment of male hypogonadism.
Expert Opin Pharmacother
2010;11(12):2095-2106.
85. Steidle CP. New advances in the treatment of hypogonadism
in the aging male.
Rev Urol
2003;5(Suppl 1):S34-S40.
86. Calof M, Singh AB, Lee ML et al. Adverse events associated
with testosterone replacement in middle-aged and older men:
a meta-analysis of randomized, placebo-controlled trials.
J Gerontol A Biol Sci Med Sci
2005;60(11):1451-1457.
87. Lakshman KM, Basaria S. Safety and efficacy of testosterone
gel in the treatment of male hypogonadism.
Clin Interv Aging
2009:4:397-412.
88. Kaufman JM, MillerMG, Garwin JL, Fitzpatrick S, McWhirter C,
Brennan JJ. Efficacy and safety study of 1.62% testosterone gel
for the treatment of hypogonadal men.
J Sex Med
2011;8(7):
2079-2089.
89. Morgentaler A, Dobs AS, Kaufman JM et al. Long acting
testosterone undecanoate therapy in men with hypogonadism:
results of a pharmacokinetic clinical study.
J Urol
2008;180(6):
2307-2313.
90. Kaminetsky JC, Moclair B, Hemani M, Sand M. A phase IV
prospectiveevaluationofthesafetyandefficacyofextendedrelease
testosterone pellets for the treatment of male hypogonadism.
J Sex Med
2011;8(4):1186-1196.
54
Miner ET AL.
